CD274 and melanoma: Disease- and progression-free survival to PLB has been documented in melanoma, lung, renal and breast carcinomas [3,4,5,6], albeit in only a small percentage of patients, marked by prominent-PD-L1 and not negligible-PD-L1 tumors.